image

Key updates

What's new on Wikilite
Section Contents
  • What's new on Wikilite
    • Key updates


Date Publication Update
31/05/2018 Miyazaki 2018 [1068]
Section 18.4.3. HLC assays in MRD assessment
31/05/2018
Chae 2018 [1066]Section 11.5.2. Comparison of Hevylite and immmunoglobulin measurements by SPE
Section 18.4.4. HLC assays improve detection of relapse
31/05/2018
Jacobs 2018 [1065]

Section 11.5.1. Comparison of Hevylite and total immunoglobulin measurements
Section 11.5.2. Comparison of Hevylite and immmunoglobulin measurements by SPE
Section 11.5.3. Comparison of Hevylite and immunofixation electrophoresis
Section 38.2. Binding Site SPAPLUS
31/05/2018 Boyle 2016 [901]
Section 11.5.1. Comparison of Hevylite and total immunoglobulin measurements
31/05/2018 Boyle 2015 [917]
Section 11.5.2. Comparison of Hevylite and immmunoglobulin measurements by SPE
31/05/2018
Katzmann 2015 [1064]Section 11.5.1. Comparison of Hevylite and total immunoglobulin measurements
Section 11.5.3. Comparison of Hevylite and immunofixation electrophoresis
31/05/2018
Paolini 2015 [1062]

Section 11.5.1. Comparison of Hevylite and total immunoglobulin measurements
Section 11.5.2. Comparison of Hevylite and immmunoglobulin measurements by SPE
Section 11.5.3. Comparison of Hevylite and immunofixation electrophoresis
Section 17.4. Limitations of electrophoresis
31/05/2018 Eckold 2010 [1067]
Section 11.5.3. Comparison of Hevylite and immunofixation electrophoresis
31/05/2018
Bradwell 2009 [127]Section 11.5.1. Comparison of Hevylite and total immunoglobulin measurements
Section 11.5.3. Comparison of Hevylite and immunofixation electrophoresis
10/05/2018 Cancer Research UK Myeloma Survival Statistics 2018
[1054]
*NEW* Figure 12.3. Age-standardised five-year myeloma survival rates in England from 1971-2011
10/05/2018 Krok-Schoen 2018
[1055]
Section 12.2. Multiple myeloma and related malignant disorders
30/04/2018
Bosello 2018 [1051] *NEW* Section 35.4.4. Systemic sclerosis
30/04/2018
Lanteri 2014 [1050]*NEW* Section 35.4.4. Systemic sclerosis
30/04/2018
Steiner 2018 [1049]Section 26.4.1. Monoclonal gammopathy of renal significance
30/04/2018
Fernandez de Larrea 2018 [1048]Section 14.4. The prognostic value of changes in monoclonal protein concentration
30/04/2018
Bossuyt 2018
[1046]
Section 7.4. Antigen excess
Section 7.4.1. Incidence of antigen excess
Section 8.4.4. Antigen excess
30/04/2018
Sachchithanantham 2016 [1045]
Section 28.4. Prognostic value of sFLCs at diagnosis
25/04/2018
Kyle 2003 [355]Section 7.7. Biclonal gammopathies
Section 17.1. Intact immunoglobulin multiple myeloma: Introduction
25/04/2018
Campbell 2017 [1041]Section 7.7. Biclonal gammopathies
*NEW* Figure 7.7. sFLC concentrations at disease presentation in biclonal gammopathy MM patients.
Section 17.1. Intact immunoglobulin multiple myeloma: Introduction
Section 17.2. Free light chains at diagnosis
Section 19.2. Clonal populations in multiple myeloma
25/04/2018 Kyle 1981 [1042]Section 17.1. Intact immunoglobulin multiple myeloma: Introduction
25/04/2018
Lohr 2014 [1043]
Section 19.2. Clonal populations in multiple myeloma
23/04/2018
Kumar 2018 [1040]Section 25.8. NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Multiple Myeloma V.4.2018
29/03/2018
Jimenez 2018 [1023]Section 13.2.2. Prognostic value of Hevylite in MGUS
28/03/2018
Premuzic 2018 [1034]Section 27.4.1. Plasma exchange
27/03/2018
Palladini 2018
[1032]
Section 28.4. Prognostic value of sFLCs at diagnosis
Section 28.5. Patients with low amyloidogenic FLCs have distinct clinical features
Section 28.8. Prognostic value of sFLC response
Section 28.8.1. sFLC response predicting cardiac outcomes
Section 28.8.2. sFLC response and renal outcome
27/03/2018
Dispenzieri 2018
[1033]
Section 28.8. Prognostic value of sFLC response
27/03/2018
Hajek 2017 [1029]Section 13.1. MGUS definition and frequency
Section 13.2. Risk factors for MGUS progression
Section 13.2.1. Prognostic value of serum FLCs in MGUS
Section 13.3.1. MGUS consistently precedes MM
23/03/2018
Landgren 2017 [1027]Section 13.1. MGUS definition and frequency
15/03/2018
Zeman 2018 [1026]Section 36.2. CSF FLCs as a marker of intrathecal immunoglobulin synthesis
15/03/2018
Gurtner 2018 [1025]Section 7.1.4. Sample and reagent stability
Section 36.2. CSF FLCs as a marker of intrathecal immunoglobulin synthesis
12/03/2018
Manwani 2018 [1024]Section 28.8. Prognostic value of sFLC response
28/02/2018
Correia 2017 [1018]Section 26.4.1. Monoclonal gammopathy of renal significance
28/02/2018
D'Souza 2016 [1019]Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Section 20.5. HLC analysis during response assessment
28/02/2018
Suehara 2017 [1020]Section 20.5. HLC analysis during response assessment
28/02/2018
D'Auria 2017 [1021]Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Section 20.5. HLC analysis during response assessment
25/01/2018
Kyle 2018 [1016]Section 13.3. MGUS as the precursor condition for MM and related disorders
25/01/2018
Kristinsson 2009 [1017]Section 13.3. MGUS as the precursor condition for MM and related disorders
24/01/2018
Palumbo 2015 [1012]
Section 20.1. Multiple Myeloma Prognosis: Introduction
16/01/2018
Thompson 2018[1011]
Section 3.6.1. Cerebrospinal fluid and free light chains: Introduction
12/01/2018
ASH Abstracts Section 28.7. Prognostic value of sFLC response
22/12/2017
Valencia-Vera 2017 [999]Section 36.2. CSF FLCs as a marker of intrathecal immunoglobulin synthesis
21/12/2017
Yagci 2015 [1007]Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Tacchetti 2016 [1006]Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Pratt 2015 [1005]Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Gentili 2015 [1004]Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Martinez-Lopez 2015 [1003]Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Garcia 2016 [1002]Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Fraser 2017 [1008]Section 35.2. Chronic Kidney Disease
Tandon 2017 [1000]Section 28.7. Prognostic value of sFLC response
Bossuyt 2017 [1001]Section 8.6.1. Comparison of absolute values
Section 8.7. Compliance with guidelines
17/11/2017
ASH abstracts Section 14.1. Introduction
Section 14.2. Monoclonal sFLCs and SMM progression
Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR
Section 20.3.2. Early sFLC response predicts outcome
Section 20.5. HLC analysis during response assessment
Section 23.6. Organisational and cost implications of screening algorithms
Section 28.4. Prognostic value of sFLCs at diagnosis
Section 28.5. Monitoring patients with AL amyloidosis
Section 32.1. Waldenström's macroglobulinaemia Introduction
Section 32.5. Use of sFLC and HLC analysis in IgM MGUS and asymptomatic WM
16/11/2017
Campbell 2017 [920]Section 8.2. Overview of commercial FLC assays
Section 8.4. Analytical performance of monoclonal and polyclonal antibody-based FLC assays
Section 8.4.1. Calibration
Section 8.5.1. Normal reference intervals
*NEW* Section 8.6.1. Comparison of absolute values
13/11/2017
Heaney 2017 [980]*NEW* Section 8.6.1. Comparison of absolute values
*NEW* Section 8.6.2. Diagnostic performance in MM
*NEW* Section 8.6.4. Monitoring MM
26/09/2017
Heaney 2017 [979]Section 8.5.2. Renal reference interval
16/11/2017
Kubicki 2017 [985]*NEW* Section 8.6.4. Monitoring MM
Lutteri 2015 [982]*NEW* Section 8.6.4. Monitoring MM
*NEW* Figure 8.11. Freelite indicates LCMM progressive disease before N Latex FLC.
Popat 2015 [984]*NEW* Section 8.6.4. Monitoring MM
Butticaz 2015 [983]*NEW* Section 8.6.4. Monitoring MM
Deutscher-Chertow 2014 [981]*NEW* Section 8.6.4. Monitoring MM
13/11/2017
Michallet 2017 [978]Section 18.4.1. HLC assays are quantitative and non-subjective
Section 18.4.5. Discrepancies between HLC and IFE during follow-up
Section 20.5. HLC analysis during response assessment
Section 20.6. Prognostic value of combining sFLC and HLC measurements
26/09/2017
Rezk 2017 [976]Section 28.7.2. sFLC response and renal outcome
26/09/2017
Dittrich 2017 [973]*NEW* Section 28.4.1. Patients with low amyloidogenic FLCs at diagnosis have distinct clinical features
26/09/2017
Milani 2017 [974]*NEW* Section 28.4.1. Patients with low amyloidogenic FLCs at diagnosis have distinct clinical features
26/09/2017
Sidana 2017 [975]*NEW* Section 28.4.1. Patients with low amyloidogenic FLCs at diagnosis have distinct clinical features
11/09/2017
AACC 2017 abstracts Section 11.4. Antigen excess
Section 11.5.1. Comparison of Hevylite and total immunoglobulin measurements
Section 13.1. MGUS definition and frequency
Section 16.3. Monitoring nonsecretory multiple myeloma
Section 23.1. Introduction
Section 35.4.3. Rheumatoid arthritis
Section 36.2. CSF FLCs as a marker of intrathecal immunoglobulin synthesis
11/09/2017
Fouquet 2017 [966]Section 18.4.1. HLC assays are quantitative and non-subjective
Section 18.4.4. HLC assays improve detection of relapse
07/07/2017
EHA 2017 abstracts Section 14.4. The prognostic value of changes in monoclonal protein concentration
Section 15.1. Diagnosis of light chain multiple myeloma
Section 15.2. Monitoring light chain multiple myeloma
Section 17.6. Immunoglobulin HLC immunoassays (Hevylite) at diagnosis
Section 20.3.1. Normalisation of the sFLC ratio and importance of a sCR

Figures

References